Prescribing trends of inhaler treatments for asthma and chronic obstructive pulmonary disease within a resource-constrained environment in the Scottish national health service: findings and implications

Holly McCabe, Brian Godman, Amanj Kurdi, Katie Johnston, Sean MacBride-Stewart, Janey Lennon, Simon Hurding, Marion Bennie, Alec Morton

Research output: Contribution to journalArticle

Abstract

Background: There is an increasing prevalence of asthma and chronic obstructive pulmonary disease (COPD) worldwide, leading to increased inhaler use. However, there are concerns with inhaler compliance resulting in different patented inhalers and longer-acting formulations. As a result, inhalers are now among the highest expenditure items in ambulatory care in Scotland leading to multiple initiatives to keep within budget without compromising care. Method: This study assesses inhaler utilization and expenditure between 2001 and 2017 alongside health authority initiatives. Results: There was an increase by 137% in inhaler utilization between 2001 and 2017, and a two-fold increase in expenditure, driven by the increasing use of patented combination inhalers to address concerns. This is very different to the oral markets where expenditure on proton pump inhibitors, statins, and antihypertensives have fallen considerably recently despite increased volumes due to the increasing use of low-cost generics. However, inhaler expenditure has started to fall with an increasing use of lower cost combinations and initiatives to reduce the steroid burden alongside monitoring patient care. Conclusion: Challenges with using and changing inhalers has meant this market has not followed other high-volume drug classes following patent loss. This is starting to change, with the situation monitored to enhance efficient prescribing alongside continued good quality care.

LanguageEnglish
Pages679-689
Number of pages11
JournalExpert Review of Respiratory Medicine
Volume13
Issue number7
Early online date12 Jun 2019
DOIs
Publication statusPublished - 3 Jul 2019

Fingerprint

Nebulizers and Vaporizers
National Health Programs
Chronic Obstructive Pulmonary Disease
Asthma
Health Expenditures
Therapeutics
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Costs and Cost Analysis
Quality of Health Care
Proton Pump Inhibitors
Scotland
Budgets
Ambulatory Care
Antihypertensive Agents
Patient Care
Steroids
Health

Keywords

  • asthma
  • COPD
  • inhalers
  • Scottish NHS
  • expenditure
  • reforms
  • drug utilisation

Cite this

@article{76ef0f4e0c484a18b778f42956fd0b25,
title = "Prescribing trends of inhaler treatments for asthma and chronic obstructive pulmonary disease within a resource-constrained environment in the Scottish national health service: findings and implications",
abstract = "Background: There is an increasing prevalence of asthma and chronic obstructive pulmonary disease (COPD) worldwide, leading to increased inhaler use. However, there are concerns with inhaler compliance resulting in different patented inhalers and longer-acting formulations. As a result, inhalers are now among the highest expenditure items in ambulatory care in Scotland leading to multiple initiatives to keep within budget without compromising care. Method: This study assesses inhaler utilization and expenditure between 2001 and 2017 alongside health authority initiatives. Results: There was an increase by 137{\%} in inhaler utilization between 2001 and 2017, and a two-fold increase in expenditure, driven by the increasing use of patented combination inhalers to address concerns. This is very different to the oral markets where expenditure on proton pump inhibitors, statins, and antihypertensives have fallen considerably recently despite increased volumes due to the increasing use of low-cost generics. However, inhaler expenditure has started to fall with an increasing use of lower cost combinations and initiatives to reduce the steroid burden alongside monitoring patient care. Conclusion: Challenges with using and changing inhalers has meant this market has not followed other high-volume drug classes following patent loss. This is starting to change, with the situation monitored to enhance efficient prescribing alongside continued good quality care.",
keywords = "asthma, COPD, inhalers, Scottish NHS, expenditure, reforms, drug utilisation",
author = "Holly McCabe and Brian Godman and Amanj Kurdi and Katie Johnston and Sean MacBride-Stewart and Janey Lennon and Simon Hurding and Marion Bennie and Alec Morton",
year = "2019",
month = "7",
day = "3",
doi = "10.1080/17476348.2019.1624528",
language = "English",
volume = "13",
pages = "679--689",
journal = "Expert Review of Respiratory Medicine",
issn = "1747-6348",
number = "7",

}

TY - JOUR

T1 - Prescribing trends of inhaler treatments for asthma and chronic obstructive pulmonary disease within a resource-constrained environment in the Scottish national health service

T2 - Expert Review of Respiratory Medicine

AU - McCabe, Holly

AU - Godman, Brian

AU - Kurdi, Amanj

AU - Johnston, Katie

AU - MacBride-Stewart, Sean

AU - Lennon, Janey

AU - Hurding, Simon

AU - Bennie, Marion

AU - Morton, Alec

PY - 2019/7/3

Y1 - 2019/7/3

N2 - Background: There is an increasing prevalence of asthma and chronic obstructive pulmonary disease (COPD) worldwide, leading to increased inhaler use. However, there are concerns with inhaler compliance resulting in different patented inhalers and longer-acting formulations. As a result, inhalers are now among the highest expenditure items in ambulatory care in Scotland leading to multiple initiatives to keep within budget without compromising care. Method: This study assesses inhaler utilization and expenditure between 2001 and 2017 alongside health authority initiatives. Results: There was an increase by 137% in inhaler utilization between 2001 and 2017, and a two-fold increase in expenditure, driven by the increasing use of patented combination inhalers to address concerns. This is very different to the oral markets where expenditure on proton pump inhibitors, statins, and antihypertensives have fallen considerably recently despite increased volumes due to the increasing use of low-cost generics. However, inhaler expenditure has started to fall with an increasing use of lower cost combinations and initiatives to reduce the steroid burden alongside monitoring patient care. Conclusion: Challenges with using and changing inhalers has meant this market has not followed other high-volume drug classes following patent loss. This is starting to change, with the situation monitored to enhance efficient prescribing alongside continued good quality care.

AB - Background: There is an increasing prevalence of asthma and chronic obstructive pulmonary disease (COPD) worldwide, leading to increased inhaler use. However, there are concerns with inhaler compliance resulting in different patented inhalers and longer-acting formulations. As a result, inhalers are now among the highest expenditure items in ambulatory care in Scotland leading to multiple initiatives to keep within budget without compromising care. Method: This study assesses inhaler utilization and expenditure between 2001 and 2017 alongside health authority initiatives. Results: There was an increase by 137% in inhaler utilization between 2001 and 2017, and a two-fold increase in expenditure, driven by the increasing use of patented combination inhalers to address concerns. This is very different to the oral markets where expenditure on proton pump inhibitors, statins, and antihypertensives have fallen considerably recently despite increased volumes due to the increasing use of low-cost generics. However, inhaler expenditure has started to fall with an increasing use of lower cost combinations and initiatives to reduce the steroid burden alongside monitoring patient care. Conclusion: Challenges with using and changing inhalers has meant this market has not followed other high-volume drug classes following patent loss. This is starting to change, with the situation monitored to enhance efficient prescribing alongside continued good quality care.

KW - asthma

KW - COPD

KW - inhalers

KW - Scottish NHS

KW - expenditure

KW - reforms

KW - drug utilisation

UR - https://www.tandfonline.com/loi/ierx20

U2 - 10.1080/17476348.2019.1624528

DO - 10.1080/17476348.2019.1624528

M3 - Article

VL - 13

SP - 679

EP - 689

JO - Expert Review of Respiratory Medicine

JF - Expert Review of Respiratory Medicine

SN - 1747-6348

IS - 7

ER -